PRELID3A

Across TCGA pan-cancer cohorts, PRELID3A mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PRELID3A data layer compared with 27 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PRELID3A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRELID3A expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM are the cancer types where PRELID3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.649	0.260	.006	29	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

PRELID3A–GBM (OS)

Open the GBM breakdown →